04-11-2024 |
AH |
|
AQST |
Aquestive Therapeutics, Inc. |
499.92 |
-0.13 |
-0.12 |
-0.03 |
Aquestive Therapeutics GAAP EPS of -$0.13 in-line, revenue of $13.54M beats by $0.86M [11/4/2024 4:42 PM] |
4.78 |
-0.38 (-7.28%) |
5.03 |
-0.12 (-2.33%) |
1.52 - 6.23 |
3,329,470 |
1,570,000 |
8,661 |
|
|
06-08-2024 |
AH |
|
AQST |
Aquestive Therapeutics, Inc. |
326.83 |
-0.03 |
-0.11 |
-0.10 |
Aquestive Therapeutics GAAP EPS of -$0.03 beats by $0.09, revenue of $20.09M beats by $7.71M [8/6/2024 4:30 PM] |
3.43 |
0.03 (0.88%) |
3.60 |
0.20 (5.88%) |
1.25 - 6.23 |
1,160,380 |
1,550,000 |
24,451 |
|
|
07-05-2024 |
AH |
|
AQST |
Aquestive Therapeutics |
299.00 |
-0.17 |
-0.09 |
0.00 |
Aquestive Therapeutics GAAP EPS of -$0.17, revenue of $12.05M [5/7/2024 5:27 PM] |
3.10 |
-0.27 (-8.14%) |
3.15 |
-0.23 (-6.80%) |
1.25 - 6.23 |
2,503,072 |
2,690,000 |
140,896 |
|
|
05-03-2024 |
PM |
|
AQST |
Aquestive Therapeutics |
245.00 |
-0.12 |
-0.08 |
0.00 |
Aquestive Therapeutics reports mixed Q4 results; initiates FY24 outlook [3/6/2024 12:58 AM] |
5.07 |
0.88 (21.00%) |
4.10 |
-0.09 (-2.15%) |
0.72 - 5.19 |
6,696,551 |
3,390,000 |
151,901 |
|
|
06-11-2023 |
AH |
|
AQST |
Aquestive Therapeutics, Inc. |
88.89 |
-0.03 |
-0.11 |
-0.23 |
Aquestive Therapeutics GAAP EPS of -$0.03 beats by $0.09, revenue of $13M beats by $1.49M [11/6/2023 4:55 PM] |
1.73 |
0.10 (6.13%) |
1.64 |
0.01 (0.61%) |
0.72 - 2.69 |
211,189 |
170,000 |
7,128 |
|
|
07-08-2023 |
AH |
|
AQST |
Aquestive Therapeutics, Inc. |
121.91 |
-0.10 |
-0.11 |
-0.36 |
Aquestive Therapeutics GAAP EPS of -$0.10 beats by $0.01, revenue of $13.24M beats by $2.23M [8/7/2023 4:05 PM] |
1.97 |
-0.08 (-3.90%) |
2.02 |
-0.03 (-1.46%) |
0.72 - 2.69 |
686,967 |
610,000 |
14,394 |
|
|
02-05-2023 |
AH |
4:00 PM ET (May 2) |
AQST |
Aquestive Therapeutics, Inc. |
70.96 |
0.11 |
-0.10 |
-0.32 |
Aquestive Therapeutics reports Q1 results, raises FY 2023 revenue guidance [5/2/2023 5:11 PM] |
1.70 |
0.31 (21.94%) |
1.40 |
0.01 (0.72%) |
0.62 - 1.80 |
1,434,919 |
220,000 |
6,877 |
|
|
07-03-2023 |
AH |
4:00 PM ET (Mar 7) |
AQST |
Aquestive Therapeutics, Inc. |
42.27 |
-0.23 |
-0.21 |
-0.38 |
Aquestive Therapeutics GAAP EPS of -$0.23 in-line, revenue of $10.68M beats by $0.26M [3/7/2023 4:05 PM] |
0.86 |
0.01 (1.18%) |
0.82 |
-0.02 (-2.94%) |
0.62 - 2.95 |
468,475 |
300,000 |
5,475 |
|
|
01-11-2022 |
AH |
4:00 PM ET (Nov 1) |
AQST |
Aquestive Therapeutics, Inc. |
45.88 |
-0.23 |
-0.30 |
-0.37 |
Aquestive Therapeutics GAAP EPS of -$0.23 beats by $0.07, revenue of $11.46M beats by $0.42M [11/1/2022 4:42 PM] |
0.8349 |
-0.02 (-2.41%) |
0.90 |
0.04 (4.85%) |
0.62 - 6.40 |
318,985 |
310,000 |
6,828 |
|
|
02-08-2022 |
AH |
5:40 PM ET (Aug 2) |
AQST |
Aquestive Therapeutics, Inc. |
44.74 |
-0.36 |
-0.41 |
-0.33 |
Aquestive Therapeutics GAAP EPS of -$0.36 in-line, revenue of $13.27M beats by $2.7M [8/2/2022 5:02 PM] |
0.8379 |
-0.04 (-4.75%) |
0.92 |
0.04 (4.58%) |
0.62 - 6.40 |
693,418 |
340,000 |
795 |
|
|
03-05-2022 |
AH |
4:55 PM ET (May 3) |
AQST |
Aquestive Therapeutics |
58.00 |
-0.32 |
-0.45 |
0.00 |
Aquestive Therapeutics GAAP EPS of -$0.32 beats by $0.09, revenue of $12.27M beats by $2.15M [5/3/2022 5:48 PM] |
1.43 |
0.06 (4.38%) |
1.49 |
0.12 (8.76%) |
1.25 - 6.40 |
452,866 |
410,000 |
3,653 |
|
|
08-03-2022 |
AH |
4:30 PM ET (Mar 8) |
AQST |
Aquestive Therapeutics, Inc. |
116.48 |
-0.38 |
-0.37 |
-0.60 |
Aquestive Therapeutics GAAP EPS of -$1.85 misses by $0.36, revenue of $50.83M beats by $1.73M [3/8/2022 5:07 PM] |
2.86 |
0.04 (1.42%) |
2.75 |
-0.07 (-2.48%) |
2.02 - 6.40 |
211,626 |
330,000 |
336 |
|
|
02-11-2021 |
AH |
5:55 PM ET (Nov 2) |
AQST |
Aquestive Therapeutics, Inc. |
196.38 |
-0.37 |
-0.40 |
-0.49 |
Aquestive Therapeutics EPS beats by $0.06, beats on revenue [11/2/2021 5:17 PM] |
5.92 |
0.56 (10.45%) |
5.30 |
-0.06 (-1.12%) |
3.10 - 8.06 |
1,344,355 |
750,000 |
10,110 |
|
|
03-08-2021 |
AH |
7:55 PM ET (Aug 3) |
AQST |
Aquestive Therapeutics, Inc. |
118.92 |
-0.33 |
-0.42 |
-0.07 |
Aquestive Therapeutics EPS beats by $0.10, beats on revenue [8/3/2021 5:57 PM] |
3.67 |
0.42 (12.92%) |
3.48 |
0.23 (7.08%) |
3.10 - 9.46 |
2,700,110 |
260,000 |
111,334 |
|
|
04-05-2021 |
AH |
5:50 PM ET (May 4) |
AQST |
Aquestive Therapeutics, Inc. |
148.84 |
-0.41 |
-0.44 |
-0.49 |
Aquestive Therapeutics EPS beats by $0.01, beats on revenue [5/4/2021 11:44 PM] |
3.85 |
0.20 (5.48%) |
3.85 |
0.20 (5.48%) |
3.57 - 9.46 |
564,095 |
570,000 |
2,832 |
|
|
09-03-2021 |
AH |
4:30 PM ET (Mar 9) |
AQST |
Aquestive Therapeutics, Inc. |
148.26 |
-0.60 |
-0.46 |
-0.48 |
Aquestive Therapeutics EPS misses by $0.10, beats on revenue [3/9/2021 6:01 PM] |
4.76 |
0.29 (6.49%) |
4.35 |
-0.12 (-2.68%) |
1.41 - 9.46 |
864,252 |
1,134,667 |
33,041 |
|
-
Aquestive Therapeutics EPS misses by $0.10, beats on revenue [3/9/2021 6:01 PM]
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline AQST [Mar-08-21 04:46PM]
-
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Mar-08-21 12:30PM]
-
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors [Mar-08-21 12:00PM]
-
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors [Mar-08-21 11:10AM]
-
Aquestive Therapeutics Earnings Preview [Mar-08-21 10:07AM]
-
AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Mar-08-21 10:00AM]
-
AQST Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Mar-09-21 10:00AM]
-
INVESTOR DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Mar-09-21 11:10AM]
-
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update [Mar-09-21 05:49PM]
-
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates [Mar-09-21 07:05PM]
-
Aquestive Therapeutics, Inc. to Host Earnings Call [Mar-10-21 05:15AM]
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline AQST [Mar-10-21 10:00AM]
-
AQST Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Mar-10-21 10:00AM]
-
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Mar-10-21 11:45AM]
-
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST) [Mar-10-21 01:00PM]
-
Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Call Transcript [Mar-10-21 01:30PM]
|
04-11-2020 |
AH |
4:00 PM ET (Nov 4) |
AQST |
Aquestive Therapeutics, Inc. |
161.38 |
-0.49 |
-0.50 |
-0.54 |
Aquestive Therapeutics EPS misses by $0.04, misses on revenue, revised FY20 guidance [11/4/2020 4:49 PM] |
5.46 |
0.18 (3.41%) |
5.11 |
-0.17 (-3.22%) |
1.41 - 10.00 |
768,823 |
516,278 |
3,443 |
|
|
04-08-2020 |
AH |
4:05 PM ET (Aug 4) |
AQST |
Aquestive Therapeutics, Inc. |
176.64 |
-0.07 |
-0.43 |
-0.82 |
Aquestive Therapeutics EPS beats by $0.36, beats on revenue [8/4/2020 4:13 PM] |
6.08 |
0.59 (10.75%) |
5.83 |
0.34 (6.19%) |
1.41 - 10.00 |
715,836 |
573,397 |
19,106 |
|
|
05-05-2020 |
AH |
4:30 PM ET (May 5) |
AQST |
Aquestive Therapeutics, Inc. |
140.04 |
-0.49 |
-0.52 |
-0.59 |
Aquestive Therapeutics EPS misses by $0.04, misses on revenue [5/5/2020 4:15 PM] |
4.50 |
0.0 (0.00%) |
4.55 |
0.05 (1.11%) |
1.41 - 10.00 |
790,262 |
744,864 |
2,974 |
|
|